{{post_title}}

Une thérapie basée sur l’ARNm, administrée à des animaux via des nanoparticules (qui permettent d’acheminer le traitement directement aux poumons), a réussi à produire 10 protéines dans les poumons. Cependant, les chercheurs doivent augmenter les niveaux de production avant de pouvoir envisager des essais sur l’homme.

“La thérapie fonctionne une fois qu’elle atteint nos cellules”, explique Bogunovic, “mais la délivrance des acides nucléiques – comme l’ADN ou l’ARN – aux tissus spécifiques nécessitant une protection reste le plus grand obstacle.” Les chercheurs s’efforcent également de prolonger la durée de la protection antivirale, actuellement estimée à trois à quatre jours.

“Nos recherches démontrent la valeur de la recherche motivée par la curiosité”, souligne Bogunovic. “Nous ne cherchions pas initialement un antiviral, mais nos travaux sur des patients atteints de maladies rares ouvrent la voie au développement d’un potentiel traitement antiviral à large spectre.”

Référence : “An mRNA-based broad-spectrum antiviral inspired by ISG15 deficiency protects against viral infections in vitro and in vivo” par Yemsratch T. Akalu, Roosheel S. Patel, Justin Taft, Rodrigo Canas-Arranz, Rachel Geltman, Ashley Richardson, Sofija Buta.

Okay, here’s an optimization of teh provided text, focusing on clarity, conciseness, and impact. I’ve aimed to highlight the key challenges and potential of the research. I’ve provided a few options, ranging from moderate to more aggressive editing.

Understanding the Goal:

Before diving in,let’s clarify the likely goal of this text. It seems to be a snippet from a science news article or press release. Thus, the optimization should:

Be accessible to a general audience. (Avoid overly technical jargon where possible,or explain it briefly.)
Emphasize the meaning of the findings. (Why is this crucial?)
Highlight the next steps. (What needs to happen before this becomes a treatment?)

When delivered to animals via nanoparticles, the therapy successfully produced 10 proteins in the lungs. Though, researchers need to increase production levels before testing in humans.

"The therapy works once it reaches our cells," explains Bogunovic, "but delivering nucleic acids - like DNA or RNA - to the specific tissues needing protection remains the biggest challenge in the field."  Researchers are also working to extend the duration of the antiviral protection,which currently lasts an estimated three to four days.

"Our findings demonstrate the value of curiosity-driven research," Bogunovic says. "We weren't initially seeking an antiviral, but our work with rare disease patients has opened the door to developing a potential global antiviral therapy."

Reference: "An mRNA-based broad-spectrum antiviral inspired by ISG15 deficiency protects against viral infections in vitro and in vivo" by Yemsratch T. Akalu, Roosheel S. Patel, Justin Taft, Rodrigo Canas-Arranz, Rachel geltman, Ashley Richardson, Sofija buta,

Combined sentences: For better flow.
Removed “probably not at high enough levels that makes us comfortable…”: Replaced with a more direct statement about needing to increase production.
simplified phrasing: Made language more accessible.
Reordered slightly: To emphasize the current limitations and then the potential.
Removed redundant phrasing: “inspired by” is implied.

Option 2: More Aggressive Optimization (conciseness & Impact)

A new therapy delivered via nanoparticles successfully produced antiviral proteins in the lungs of animals.  However, researchers are working to increase protein production before human trials can begin.

"Getting nucleic acids - DNA or RNA - to the right tissues is the biggest hurdle," says Bogunovic. "Once inside cells, the therapy works, but delivery is key."  The current antiviral protection lasts approximately three to four days, and researchers are focused on extending it's duration.

"This research, born from studying rare diseases, has unexpectedly revealed the potential for a universal antiviral," Bogunovic explains.

Reference: "An mRNA-based broad-spectrum antiviral inspired by ISG15 deficiency protects against viral infections in vitro and in vivo" by Yemsratch T. Akalu, Roosheel S. Patel, Justin Taft, Rodrigo Canas-Arranz, Rachel Geltman, Ashley Richardson, Sofija Buta,

Changes Made (Option 2):

Stronger opening: More direct and impactful.
Further simplified language: Removed more jargon.
More concise phrasing: Cut needless words.
Combined sentences more aggressively: For brevity.
Replaced “demonstrates the value of” with “has unexpectedly revealed”: More engaging.

Researchers have developed a nanoparticle-delivered therapy that produces antiviral proteins in the lungs, showing promise as a broad-spectrum antiviral.  Key challenges remain in scaling up protein production and extending the duration of protection, currently three to four days.

"Efficient delivery of DNA or RNA to target tissues is the biggest obstacle," says Bogunovic. "But this research, stemming from studies of rare diseases, opens the door to a potential universal antiviral treatment."

Reference: "An mRNA-based broad-spectrum antiviral inspired by ISG15 deficiency protects against viral infections in vitro and in vivo" by Yemsratch T. Akalu, Roosheel S. Patel,Justin Taft,Rodrigo Canas-Arranz,Rachel Geltman,Ashley richardson,Sofija Buta,

Target Audience: Who are you writing for? A more technical audience would tolerate (and perhaps expect) more jargon.
context: Where will this text appear? (e.g., a news article, a scientific abstract, a grant proposal).
“Nanoparticles”: Consider briefly explaining why nanoparticles are used.(e.g.,”Nanoparticles help deliver the therapy directly to the lungs…”)
“Universal Antiviral”: this is a big claim. Be careful about overstating the potential.Perhaps “broad-spectrum antiviral” is more accurate.
ISG15 Deficiency: If this is importent to the story,briefly explain what ISG15 deficiency is and why it inspired the research.

To help me refine the optimization further, please tell me:

Who is the intended audience?
Where will this text be used?
* Is there anything specific you want to emphasize? (e.g., the animal studies, the delivery challenge, the potential for a universal antiviral).